Perspective Therapeutics (CATX) EBITDA Margin Growth (1y) (2011 - 2023)
Powered by 
Analysis
Perspective Therapeutics (CATX) EBITDA Margin Growth (1y) (2011 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.37 Bn | 192.39 Bn | 7.24 Bn | 602.00 |
| 2 | Gilead Sciences | 180.14 Bn | 176.96 Bn | 6.22 Bn | -16,814.00 |
| 3 | Vertex Pharmaceuticals | 131.30 Bn | 123.45 Bn | 2.84 Bn | -143.00 |
| 4 | Regeneron Pharmaceuticals | 81.71 Bn | 73.72 Bn | 3.93 Bn | 78.00 |
| 5 | Argenx Se | 60.30 Bn | 55.12 Bn | 1.37 Bn | 1,135.00 |
| 6 | Moderna | 53.94 Bn | 48.80 Bn | 52.00 Mn | 7,666.00 |
| 7 | Alnylam Pharmaceuticals | 33.23 Bn | 29.92 Bn | 992.69 Mn | 2,002.00 |
| 8 | Biogen | 31.82 Bn | 30.54 Bn | 1.96 Bn | -2,881.00 |
| 9 | Roivant Sciences | 29.04 Bn | 29.04 Bn | 1.16 Mn | -1.23 Mn |
| 10 | Perspective Therapeutics | 337.22 Mn | 337.22 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | -33,840.00 |
| Jun 30, 2023 | -40,284.00 |
| Mar 31, 2023 | -42,586.00 |
| Sep 30, 2022 | -1,913.00 |
| Jun 30, 2022 | -2,397.00 |
| Mar 31, 2022 | -1,782.00 |
| Dec 31, 2021 | -2,105.00 |
| Sep 30, 2021 | -5,874.00 |
| Jun 30, 2021 | 1,184.00 |
| Mar 31, 2021 | -1,043.00 |
| Dec 31, 2020 | 393.00 |
| Sep 30, 2020 | 616.00 |
| Jun 30, 2020 | 729.00 |
| Mar 31, 2020 | 4,142.00 |
| Dec 31, 2019 | 3,412.00 |
| Sep 30, 2019 | 6,107.00 |
| Jun 30, 2019 | 8,839.00 |
| Mar 31, 2019 | 2,468.00 |
| Dec 31, 2018 | 2,052.00 |
| Sep 30, 2018 | 3,098.00 |